2013•Chinese Journal of AsthmaRequires access

Resistance mechanisms of EGFR-TKI and new strategies for overcoming resistance in non-small cell lung cancer

Hao Zhao, Minhua Shi

Abstract

In recent years,epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) erlotinib and gefitinib have shown dramatic effects against EGFR mutant non-small cell lung cancer.However,tumor become resistant to EGFR-TKI by various mechanisms and may finally lead to failure in disease control.In this paper,we reviews mechanisms of EGFR-TKI resistance in non-small cell lung cancer and therapeutic strategies to overcome EGFR-TKI resistance. Key words: Non-small cell lung cancer; Epidermal growth factor receptor-tyrosine kinase inhibitor ; Resistance mechanism

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Gefitinib, Medicine, Erlotinib, Lung cancer, Epidermal growth factor receptor, Tyrosine kinase, Cancer research, Epidermal growth factor